AstraZeneca, Chemical Development
Macclesfield, England, United Kingdom
David Laffan is currently Director of Chemical Development in AstraZeneca Macclesfield, where he runs a multidiscplinary group (chemists, analysts, engineers, crystallisation scientists etc) working on all stages of Drug Substance development. His group is reponsible for all of the late stage Drug Substance activities on the oligopeptide portfolio in AstraZeneca and is involved in several cross pharma pre-competitive collaborations. He is a synthetic chemist by training, completing his PhD with Ian Paterson at Cambridge, spending some time in the contract manufacturing industry (Lonza, Switzerland) before moving to Pharmaceuticals with Zeneca/AstraZeneca. Over his career he has led development activities for a number of successful medicines, including Crestor, Faslodex and most recently Calquence.
Tuesday, November 3, 2020
11:00 AM – 11:30 AM ET